- Home
- CMAX vs CVKD Comparison
CMAX vs CVKD Comparison
Compare CMAX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- CVKD
- Stock Information
- Founded
- CMAX 2011
- CVKD 2022
- Country
- CMAX United States
- CVKD United States
- Employees
- CMAX N/A
- CVKD N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CMAX Technology
- CVKD Health Care
- Exchange
- CMAX Nasdaq
- CVKD Nasdaq
- Market Cap
- CMAX 7.6M
- CVKD 17.1M
- IPO Year
- CMAX N/A
- CVKD 2023
- Fundamental
- Price
- CMAX $1.85
- CVKD $15.24
- Analyst Decision
- CMAX Hold
- CVKD Strong Buy
- Analyst Count
- CMAX 2
- CVKD 2
- Target Price
- CMAX $33.20
- CVKD $52.50
- AVG Volume (30 Days)
- CMAX 58.0K
- CVKD 59.6K
- Earning Date
- CMAX 11-07-2024
- CVKD 11-08-2024
- Dividend Yield
- CMAX N/A
- CVKD N/A
- EPS Growth
- CMAX N/A
- CVKD N/A
- EPS
- CMAX N/A
- CVKD N/A
- Revenue
- CMAX $784,551,000.00
- CVKD N/A
- Revenue This Year
- CMAX $13.01
- CVKD N/A
- Revenue Next Year
- CMAX $32.42
- CVKD N/A
- P/E Ratio
- CMAX N/A
- CVKD N/A
- Revenue Growth
- CMAX 9.06
- CVKD N/A
- 52 Week Low
- CMAX $1.55
- CVKD $5.40
- 52 Week High
- CMAX $74.70
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- CMAX 46.01
- CVKD 60.90
- Support Level
- CMAX $1.60
- CVKD $11.19
- Resistance Level
- CMAX $2.39
- CVKD $15.93
- Average True Range (ATR)
- CMAX 0.19
- CVKD 1.36
- MACD
- CMAX 0.07
- CVKD 0.23
- Stochastic Oscillator
- CMAX 32.50
- CVKD 61.01
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.